TherapeuticsMD (TXMD) Competitors $1.55 0.00 (0.00%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TXMD vs. OSMT, OMGA, VRCA, SPRO, EPRX, ENTX, SYRS, VHAQ, ONCO, and ZIVOShould you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Osmotica Pharmaceuticals (OSMT), Omega Therapeutics (OMGA), Verrica Pharmaceuticals (VRCA), Spero Therapeutics (SPRO), Eupraxia Pharmaceuticals (EPRX), Entera Bio (ENTX), Syros Pharmaceuticals (SYRS), Viveon Health Acquisition (VHAQ), Onconetix (ONCO), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector. TherapeuticsMD vs. Osmotica Pharmaceuticals Omega Therapeutics Verrica Pharmaceuticals Spero Therapeutics Eupraxia Pharmaceuticals Entera Bio Syros Pharmaceuticals Viveon Health Acquisition Onconetix ZIVO Bioscience Osmotica Pharmaceuticals (NASDAQ:OSMT) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Does the media favor OSMT or TXMD? In the previous week, TherapeuticsMD had 1 more articles in the media than Osmotica Pharmaceuticals. MarketBeat recorded 1 mentions for TherapeuticsMD and 0 mentions for Osmotica Pharmaceuticals. Osmotica Pharmaceuticals' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score. Company Overall Sentiment Osmotica Pharmaceuticals Neutral TherapeuticsMD Neutral Do analysts rate OSMT or TXMD? Given Osmotica Pharmaceuticals' higher possible upside, analysts plainly believe Osmotica Pharmaceuticals is more favorable than TherapeuticsMD.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Osmotica Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ATherapeuticsMD 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the MarketBeat Community prefer OSMT or TXMD? TherapeuticsMD received 309 more outperform votes than Osmotica Pharmaceuticals when rated by MarketBeat users. Likewise, 59.75% of users gave TherapeuticsMD an outperform vote while only 57.89% of users gave Osmotica Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOsmotica PharmaceuticalsOutperform Votes7757.89% Underperform Votes5642.11% TherapeuticsMDOutperform Votes38659.75% Underperform Votes26040.25% Which has better earnings & valuation, OSMT or TXMD? TherapeuticsMD has lower revenue, but higher earnings than Osmotica Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOsmotica Pharmaceuticals$177.88M0.00-$79.59M-$1.59N/ATherapeuticsMD$1.30M13.74-$10.28MN/AN/A Is OSMT or TXMD more profitable? TherapeuticsMD has a net margin of 0.00% compared to Osmotica Pharmaceuticals' net margin of -138.76%. TherapeuticsMD's return on equity of -17.01% beat Osmotica Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Osmotica Pharmaceuticals-138.76% -81.23% -20.97% TherapeuticsMD N/A -17.01%-10.98% Which has more risk and volatility, OSMT or TXMD? Osmotica Pharmaceuticals has a beta of 2.34, meaning that its share price is 134% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Do insiders and institutionals hold more shares of OSMT or TXMD? 46.2% of Osmotica Pharmaceuticals shares are held by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are held by institutional investors. 5.2% of Osmotica Pharmaceuticals shares are held by company insiders. Comparatively, 1.2% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryTherapeuticsMD beats Osmotica Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get TherapeuticsMD News Delivered to You Automatically Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXMD vs. The Competition Export to ExcelMetricTherapeuticsMDPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.86M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.47113.8115.12Price / Sales13.74381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book0.565.324.665.02Net Income-$10.28M$153.56M$119.06M$225.46M7 Day Performance-2.57%0.12%0.79%0.37%1 Month Performance-6.12%15.23%5.65%3.57%1 Year Performance-29.59%41.16%36.76%29.42% TherapeuticsMD Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXMDTherapeuticsMD0.8331 of 5 stars$1.55flatN/A-26.1%$17.86M$1.30M0.00420OSMTOsmotica PharmaceuticalsN/AN/AN/AN/A$69.47M$177.88M-0.70302OMGAOmega Therapeutics1.4332 of 5 stars$1.26+1.6%$10.20+709.5%-17.8%$69.49M$3.09M-0.88120Gap DownVRCAVerrica Pharmaceuticals4.1939 of 5 stars$1.63-2.9%$11.40+599.0%-58.1%$69.19M$13.91M-0.8740Gap UpSPROSpero Therapeutics4.5912 of 5 stars$1.28-2.7%$7.00+449.0%+3.5%$68.83M$105.43M3.8646News CoverageHigh Trading VolumeEPRXEupraxia PharmaceuticalsN/A$2.50+2.9%N/AN/A$68.21MN/A-3.0929News CoverageGap UpENTXEntera Bio2.8986 of 5 stars$1.90+0.7%$10.00+425.3%+170.4%$68.12M$57,000.00-7.3220Short Interest ↓Positive NewsGap UpSYRSSyros Pharmaceuticals4.6718 of 5 stars$2.51-0.8%$5.00+99.2%-5.2%$67.09M$4.15M-0.58120Earnings ReportAnalyst ForecastNews CoverageGap DownVHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002ONCOOnconetix1.2631 of 5 stars$2.93-3.6%N/AN/A$65.42M$1.46M0.0012News CoveragePositive NewsZIVOZIVO BioscienceN/A$18.52-7.2%N/A+712.5%$64.64M$15,850.00-3.5210Positive News Related Companies and Tools Related Companies Osmotica Pharmaceuticals Alternatives Omega Therapeutics Alternatives Verrica Pharmaceuticals Alternatives Spero Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Entera Bio Alternatives Syros Pharmaceuticals Alternatives Viveon Health Acquisition Alternatives Onconetix Alternatives ZIVO Bioscience Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TXMD) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
